Bringing treatments to life
Accelerating value inflection with tailored IIT and IND solutions
Clinical Redefined
80% of life-saving innovations come from emerging biotechs, yet getting them to patients is where the system breaks down. Reaching human PoC remains painfully slow, capital-intensive, and high-risk. Investors increasingly want more human patient data before investing. And the regulatory and competitive landscape increasingly demands companies to move even faster, show more evidence, and stay more flexible.
More requirements. Fewer funds. Less time.
This is where Vivara Clinical comes in: to bridge the growing gap between concept and clinical proof with high-quality, faster, and more budget sensible preclinical and clinical solutions, so we can continue to see the best innovations help the most patients.
Tony Xu, PhD
Managing Director, Vivara
Vivara provides a one-stop China Pre to Clinial Solution with global reach
Vivara enables companies to seamlessly leverage the China advantage
Value ‘leakage’ with traditional R&D approach is no longer sustainable
Our 818 and tailored 828 solutions derisk investments and accelerate value inflection, while requiring less time and capital
IITs (818) have been a hot topic, because when run correctly, it provide significant strategic advantages
The key, is to run it correctly
